Abstract
Nowadays, heterocyclic compounds act as a scaffold and are the backbone of medicinal chemistry. Among all of the heterocyclic scaffolds, 1,4-Dihydropyridine (1,4-DHP) is one of the most important heterocyclic rings that possess prominent therapeutic effects in a very versatile manner and plays an important role in synthetic, medicinal, and bioorganic chemistry. The main aim of the study is to review and encompass relevant studies related to 1,4-DHP and excellent therapeutic benefits of its derivatives. An extensive review of Pubmed-Medline, Embase and Lancet’s published articles was done to find all relevant studies on the activity of 1,4-DHP and its derivatives. 1,4-DHP is a potent Voltage-Gated Calcium Channel (VGCC) antagonist derivative which acts as an anti-hypertensive, anti- anginal, anti-tumor, anti-inflammatory, anti-tubercular, anti-cancer, anti-hyperplasia, anti-mutagenic, anti-dyslipidemic, and anti-ulcer agent. From the inferences of the study, it can be concluded that the basic nucleus, 1,4-DHP which is a voltage-gated calcium ion channel blocker, acts as a base for its derivatives that possess different important therapeutic effects. There is a need of further research of this basic nucleus as it is a multifunctional moiety, on which addition of different groups can yield a better drug for its other activities such as anti-convulsant, anti-oxidant, anti-mutagenic, and anti-microbial. This review would be significant for further researches in the development of several kinds of drugs by representing successful matrix for the medicinal agents.
Keywords: 1, 4-Dihydropyridine, pyridine, Ca++channel blocker, voltage-gated calcium channel, antihypertension, therapeutic effects.
Graphical Abstract
[1]
Sharma, V.K.; Singh, S.K. Synthesis, utility and medicinal importance of 1,2 & 1,4 dihydropyridines. RSC Adv, 2017, 7, 2682-2732.
[2]
Khedkar, S.A.; Auti, P.B. 1,4-Dihydropyridines: A class of pharmacologically important molecules. Mini Rev. Med. Chem., 2014, 14(3), 282-290.
[3]
Mansoor, S.S.; Aswin, K.; Logaiya, K.; Sudhan, S.P.N. Bismuth nitrate as an efficient recyclable catalyst for the one-pot multi component synthesis of 1, 4-dihydropyridine derivatives through unsymmetrical hantzsch reaction. J. Saudi Chem. Soc., 2016, 20(1), S001-S008.
[4]
Kappe, C.O. Biologically active dihydropyrimidones of the Biginelli-type -a literature survey. Eur. J. Med. Chem., 2000, 35(12), 1043-1052.
[5]
Swarnalatha, G.; Prasanthi, G.; Sirisha, N.; Chetty, C.M. 1,4-Dihydropyridines: A multtifunctional molecule- A review. Int. J. Chemtech Res., 2011, 3, 75-89.
[6]
Stout, D.M.; Meyers, A.I. Recent advances in the chemistry of dihydropyridines. Chem. Rev., 1982, 82(2), 223-243.
[8]
Kuthan, J.; Kurfurst, A. Development in dihydropyridine chemistry. Ind. Eng. Chem. Prod. Res. Dev., 1882, 21(2), 191-261.
[9]
Hofmann, H.J.; Cimiraglia, R. Conformation of 1, 4- dihydropyridine- planar or boat-like? FBBS Lett., 1988, 241(1,2), 38-40.
[10]
Fossheim, R. Crystal structure of the dihydropyridine ca++ antagonist felodipine. Dihydropyridine binding prerequisites assessed from crystallographic data. J. Med. Chem., 1986, 29(2), 305-307.
[11]
Franckowiak, G.; Bechem, M.; Schramm, M.; Thomas, G. The optical isomers of the 1,4-dihydropyridine bay k 8644 show opposite Effects on ca channels. Eur. J. Pharmacol., 1985, 114(2), 223-226.
[12]
Goldmann, S.; Born, L.; Kazda, S.; Pittel, B.; Schramm, M. Synthesis, pharmacological effects, and conformation of 4,4-disubstituted 1,4-dihydropyridines. J. Med. Chem., 1990, 33(5), 1413-1418.
[13]
Goldmann, G.; Stoltefuss, J. 1,4-Dihydropyridines: Effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angew. Chem. Int. Ed. Engl., 1991, 30(12), 1559-1578.
[14]
Rovnyak, G.C.; Kimball, S.D.; Beyer, B.; Cucinotta, S.G.; DiMarco, J.D.; Gougoutas, J.; Hedberg, A.; Malley, M.; McCarthy, J.P.; Zhang, R.; Morelande, S. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. J. Med. Chem., 1995, 38(1), 119-129.
[16]
Zhang, L.; Song, Z.; Dong, Y.; Wang, Y.; Li, X.; Long, H.; Xu, K.; Deng, C.; Meng, M.; Yin, Y.; Xi, R. Enantiomeric separation of 1, 4-dihydropyridines by liquid-phase microextraction with supercritical fluid chromatography. J. Supercrit. Fluids, 2016, 107, 129-136.
[17]
Yu, F.; Zhou, B.; Xu, H.; Chang, K.; Shen, Y. An atom-economic green approach: Oxidative synthesis of functionalized 1,4-dihydropyridines from N,N-dimethylenaminones and amines. Tetrahedron Lett., 2015, 56(6), 837-841.
[18]
Cataldi, M.; Bruno, F. 1,4-Dihydropyridines: The multiple personalities of a blockbuster drug family. Transl. Med. UniSa, 2012, 4(2), 12-26.
[19]
Shaldam, M.A.; Elhamamsy, M.H.; Esmat, E.A.; El-moselhy, T.F. 1,4-Dihydropyridine calcium channel blockers: Homology modeling of the receptor and assessment of structure-activity relationship. ISRN Med. Chem, 2014, 2014, 1-14.
[20]
Schaller, D.; Gunduz, M.G.; Zhang, F.X.; Zamponi, G.W.; Wolber, G. Binding mechanism investigations guiding the synthesis of a novel condensed 1,4- dihydropyridine derivatives with L-/T-type calcium channel blocking activity. Eur. J. Med. Chem., 2018, 155, 1-12.
[21]
Wang, A.L.; Iadecola, C.; Wang, G. New generations of dihydropyridines for treatment of hypertension. J. Geriatr. Cardiol., 2017, 14(1), 67-72.
[22]
Fleckenstein, A.; Tritthart, H.; Flackenstein, B.; Herbst, A.; Grun, G. A new group of competitive divalent Ca-antagonists (iproveratril, D 600, prenylamine) with potent inhibitory effects on electromechanical coupling in mammalian myocardium. Pflugers Arch., 1969, 307(2), R25. [Article in German].
[23]
Coca, A.; Mazon, P.; Redon, J.; Divison, J.A.; Martínez, J.; Calvo, C.; Galceran, M.; Bareios, V.; Coll, A.R. Role of dihydropyridine calcium channel blockers in the management of hypertension. Expert Rev. Cardiovasc. Ther., 2013, 11(1), 91-105.
[24]
Wang, J.; Kario, K.; Lau, T.; Wei, Y.Q.; Park, C.G.; Kim, C.H.; Huang, J.; Zhang, W.; Li, W. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian pacific heart association. Hypertens. Res., 2011, 34(4), 423-430.
[25]
Liau, C. Barnidipine: A new calcium channel blocker for hypertension treatment. Exp. Revi. Cardio. Ther, 2005, 3(2), 207-213.
[26]
Van Zwieten, P.A. The pharmacological properties of lipophilic calcium antagonists. Blood Press. Suppl., 1998, 7(2), 5-9.
[27]
Chandra, K.S.; Ramesh, G. The fourth-generation calcium channel blocker: Cilnidipine. Ind Heart J., 2013, 65(6), 691-695.
[28]
Salazar, T.; Gonzalez, A.; Bandyopadhaya, D. Dihydropyridines as calcium channel blockers: An overview. J. Anal. Pharm. Res, 2017, 5(4), 00148.
[29]
Ozer, E.K. MiyaseGunduz, M.G.; El-Khouly. A.; Sara, Y.; Simsek, R.; Iskit, A.B.; Safak, C. Synthesis of fused 1,4-dihydropyridines as potential calcium channel blockers. Turk. J. Biochem, 2017, 43(6), 1-9.
[30]
Mohajeri, S.A.; Hosseinzadeh, H.; Salami, S.; Motamedshariaty, V.; Hadizadeh, F. Synthesis of novel 4-[1-(4-fluorobenzyl) -5-imidazolyl] dihydropyridines and studying their effects on rat blood pressure. Iran. J. Basic Med. Sci., 2011, 14(5), 451-457.
[31]
Zhou, K.; Zhao, Y.; Wang, X.; Cao, Y.; Fu, Q.; Zhang, S. Synthesis and antihypertensive activity evaluation in spontaneously hypertensive rats of nitrendipine analogs. Med. Chem. Res., 2011, 20(8), 1325-1330.
[32]
Balaev, A.N.; Eleev, A.F.; Eremin, O.G.; Fedorov, V.E. Synthesis and antihypertensive activity of 1,4-dihydropyridines containing 3-dialkylamino-2,2-dimethyl propyl fragments. Pharm. Chem. J., 2010, 44(2), 56-57.
[33]
Nekooeian, A.A.; Khalili, A.; Javidnia, K.; Mehdipour, A.R.; Miri, R. Antihypertensive effects of some new nitroxyalkyl 1, 4-dihydropyridine derivatives in the rat model of two-kidney, one-clip hypertension. Iran. J. Pharm. Res., 2009, 8(3), 193-199.
[34]
Hadizadeh, F.; Fatehi-Hassanabad, Z.; Fatehi-Hassanabad, M.; Beheshtizadeh, A.; Nabati, F. Synthesis and antihypertensive activity of novel 4-[1-(4-X-benzyl)-5-imidazolyl] dihydropyridines in the rat. Res. Pharm. Sci., 2007, 2(2), 85-90.
[35]
Liang, J.; Yeh, J.; Wang, C.; Liou, S.; Tsai, C.; Chen, I. The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display ∝-/β-adrenoceptor antagonist and long-acting antihypertensive activities. Bioorg. Med. Chem., 2002, 10, 719-730.
[36]
Ogawa, T.; Nakazato, A.; Tsuchida, K.; Hatayama, K. Synthesis and antihypertensive activity of new 1,4-dihydropyridine derivatives containing nitrooxyalkylester moieties at the 3- and 5- position. Chem. Pharm. Bull., 1993, 41(6), 1049-1054.
[37]
Bossert, B.F.; Meyer, H.; Wehinger, E. 4-Aryldihydropyridines, a new class of highly active calcium antagonists. Angew. Chem. Int. Ed. Engl., 1981, 20(9), 762-769.
[38]
Matos, H.L.S.; Masson, F.T.; Simeoni, L.A. Homem-de-mello, M. biological activity of dihydropyrimidinone (DHPM) derivatives: A systematic review. Eur. J. Med. Chem., 2018, 143, 1779-1789.
[39]
Freedman, D.D.; Waters, D.D. Dihydropyridine calcium antagonists greater vascular selectivity and some unique applications. Drugs, 1987, 34(5), 578-598.
[40]
Datar, P.A.; Auti, P.B. Design and synthesis of novel 4-substituted 1, 4-dihydropyridine derivatives as hypotensive agents. J. Saudi Chem. Soc., 2016, 20(5), 510-516.
[41]
Razzaghi-asl, N.; Miri, R.; Firuzi, O. Assessment of the cytotoxic effect of a series of 1, 4-dihydropyridine derivatives against human cancer cells. Iran. J. Pharm. Res., 2016, 15(3), 413-420.
[42]
Al-Said, M.S.; Bashandy, M.S.; Al-qasoumi, S.I.; Ghorab, M.M. Anti-breast cancer activity of some novel 1, 2-dihydropyridine, thiophene and thiazole derivatives. Eur. J. Med. Chem., 2011, 46(1), 137-141.
[43]
Goto, R.N.; Sobral, L.M.; Sousa, L.O.; Garcia, C.B.; Lopes, N.P.; Marin-Prida, J.; Ochoa-Rodriguez, E.; Verdecia-Reyes, Y.; Pardo-Andreu, G.L.; Curti, C.; Leopoldino, A.M. Anti-cancer activity of a new dihydropyridine derivative, VdiE-2N, in head and neck squamous cell carcinoma. Eur. J. Pharmacol., 2018, 819, 198-206.
[44]
Kumar, R.; Gahlyan, P.; Verma, A.; Jain, R.; Das, S.; Konwar, R.; Prasad, A.K. Design and synthesis of fluorescent symmetric bis-triazolylated-1,4-dihydropyridines as potent anti-breast cancer agents. Synth. Commun., 2018, 48(7), 778-785.
[45]
Viradiya, D.; Mirza, S.; Shaikh, F.; Kakadiya, R.; Rathod, A.; Jain, N.; Rawal, R.; Shah, A. Design and synthesis of 1,4-dihydropyridine derivatives as anti-cancer agent. Anticancer. Agents Med. Chem., 2017, 17(7), 1003-1013.
[46]
Bazargan, L.; Fouladdel, S.; Shafiee, A.; Amini, M.; Ghaffari, S.M.; Azizi, E. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro. Cell Biol. Toxicol., 2008, 24(2), 165-174.
[47]
Dhinakaran, I.; Padmini, V.; Bhuvanesh, N. One-pot synthesis of N-aryl 1,4-dihydropyridine derivatives and their biological activities. J. Chem. Sci., 2015, 127(12), 2201-2209.
[48]
Aziz, H.M.; Gomha, S.M. Synthesis and in vitro anti-breast cancer activity of some novel 1,4-dihydropyridine derivatives. Int. J. Pharm. Pharm. Sci., 2013, 5(3), 183-189.
[49]
Sirisha, K.; Achaiah, G.; Reddy, V.M. Facile synthesis and antibacterial, antitubercular and anticancer activities of novel 1, 4-dihydropyridines. Arch. Pharm. Chem. Life Sci, 2010, 343(6), 342-352.
[50]
Foroughinia, F.; Javidnia, K.; Amirghofran, Z.; Mehdipour, A.; Miri, R. Design and synthesis of new symmetrical derivatives of dihydropyridine containing a pyridyl group on the 3, 5-positions and evaluation of their cytotoxic and multidrug resistance reversal activity. J. Pharm. Pharmacol., 2008, 60(11), 1481-1489.
[51]
Saponara, S.; Ferrara, A.; Gorelli, B.; Shah, A.; Kawase, M.; Motohashi, N.; Molnar, J.; Sgaragli, G.; Fusi, F. 3,5-dibenzoyl-4-(3-phenoxyphenyl)-1, 4-dihydro-2,6-dimethylpyridine (DP7): A new multidrug resistance inhibitor devoid of effects on langendorff-perfused rat heart. Eur. J. Pharmacol., 2007, 563(1-3), 160-163.
[52]
Kawase, M.; Shah, A.; Gaveriya, H.; Motohashi, N.; Sakagami, H.; Varga, A.; Molna, J. 3,5-dibenzoyl-1,4-dihydropyridines: Synthesis and MDR reversal in tumor cells. Bioorg. Med. Chem., 2002, 10(4), 1051-1055.
[53]
Marquez, B.; Neuville, L.; Moreau, N.J.; Genet, J.; dos Santos, A.F.; Cano-de-Andrade, M.C. Sant, Ana A.E.G. Multidrug resistance reversal agent from jatropha elliptica. Phytochemistry, 2005, 66(15), 1804-1811.
[54]
Arentz, M.; Hawn, T.R. Tuberculosis infection: Insight from immunogenomics. Drug Discov. Today Dis. Mech., 2007, 4(4), 231-236.
[55]
Janin, Y.L. Antituberculosis drugs: Ten years of research. Bioorg. Med. Chem., 2007, 15(7), 2479-2513.
[56]
Lentz, F.; Reiling, N.; Martins, A.; Molnar, J.; Hilgeroth, A. Discovery of novel enhancers of isoniazid toxicity in mycobacterium tuberculosis. Molecules, 2018, 23(4)E825
[57]
Rasouli, Y.; Davood, A. Hybrid docking-QSAR studies of 1, 4-dihydropyridine-3, 5-dicarboxamides as potential antitubercular agents. Curr. Comput. Aided Drug Des, 2018, 14(1), 35-53.
[58]
Hilgeroth, A.; Reiling, N.; Hemmer, M.; Lentz, F. Discovery of novel N-phenyl 1,4 dihydropyridines with a dual mode of antimycobacterial activity. Bioorg. Med. Chem. Lett., 2016, 26(24), 5896-5898.
[59]
Iman, M. Davood, A.; Lotfinia, M.; Dehqani, G.; Sardari, S.; Azerang, P.; Amini, M. design, synthesis and anti-tubercular activity of novel 1, 4-dihydropyrine-3,5 dicarboxamide containing 4(5)-chloro-2-ethyl- 5(4)-imidazolyl moiety. Iran. J. Pharmaceut. Res., 2016, 15(4), 791-799.
[60]
Trivedi, A.R.; Dodiya, D.K.; Dholariya, B.H.; Kataria, V.B.; Bhuva, V.R.; Shah, V.H. Synthesis and biological evaluation of some novel N-aryl-1,4-dihydropyridines as potential antitubercular agents. Bioorg. Med. Chem. Lett., 2011, 21(18), 5181-5183.
[61]
Fassihi, A.; Azadpour, Z.; Delbari, N.; Saghaie, L.; Memarian, H.R.; Sabet, R.; Alborzi, A.; Miri, R.; Pourabbas, R.; Mardanehe, J.; Mousavi, P.; Moeinifardf, B.; Sadeghi-Ali, A.H. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides. Eur. J. Med. Chem., 2009, 44(8), 3253-3258.
[62]
Khoshneviszadeh, M.; Edraki, N.; Javidnia, K.; Alborzi, A.; Pourabbas, B.; Mardanehc, J.; Miri, R. Synthesis and biological evaluation of some new 1, 4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. Bioorg. Med. Chem., 2009, 17(4), 1579-1586.
[63]
Shafii, B.; Amini, M.; Akbarzadeh, T.; Shafiee, A. Synthesis and antitubercular activity of N3, N5-diaryl-4- (5-aryl isoxazole-3-yl)-1,4-dihydropyridine- 3,5-dicarboxamide. J. Sci. I.R. Iran, 2008, 19(4), 323-328.
[64]
Nasrollahi, S.M.H.; Ghasemzadeh, M.A.; Zolfaghari, M.R. Synthesis and antibacterial evaluation of somenew 1,4 dihydropyridines in the presence of Fe3O4@silica sulfonic acid nanocomposite as catalyst. Acta. Chem. Slov., 2018, 65(1), 199-207.
[65]
Ahamed, A.; Arif, I.A.; Mateen, M.; Kumar, R.S.; Idhayadhulla, A. Antimicrobial, anticoagulant, and cytotoxic evaluation of multidrug resistance of new 1,4-dihydropyridine derivatives. Saudi J. Biol. Sci., 2018, 25(6), 1227-1235.
[66]
Narsinghani, T.; Soni, L.K.; Chourey, S. Synthesis and antimicrobial activity of 1,4-dihydropyridine derivative. J. Drug Deliv. Ther., 2017, 7(7), 142-145.
[67]
Moradi, L.; Mahinpour, R.; Zahraei, Z.; Pahlevanzadeh, N. New synthetic method for the Synthesis of 1,4-dihydropyridine using aminated multiwalled carbon nanotubes as high efficient catalyst and investigation of their antimicrobial properties. J. Saudi Chem. Soc., 2018, 22(7), 876-885.
[68]
Elumalai, K.; Elumalai, M.; Eluri, K. Facile synthesis, spectral characterization, antimicrobial and in vitro cytotoxicity of novel N3, N5-diisonicotinyl-2,6-dimethyl-4-phenyl-1, 4-dihydropyridine-3,5-dicarbohydrazide derivatives. Bull. Fac. Pharm., 2016, 54(1), 77-86.
[69]
Mehta, P.; Verma, P. Antimicrobial activity of some derivatives of 1,4-dihydropyridines. J. Chem., 2013, 2013, 1-4.
[70]
Kumar, R.S.; Idhayadhulla, A.; Nasser, A.J.A.; Selvin, J. Synthesis and antimicrobial activity of a new series of 1,4-dihydropyridine derivatives. J. Serb. Chem. Soc., 2011, 76(1), 1-11.
[71]
Kumar, A.; Maurya, R.A.; Sharma, S.; Kumar, M.; Bhatia, G. Synthesis and biological evaluation of N-aryl-1,4-dihydropyridines as novel antidyslipidemic and antioxidant agents. Eur. J. Med. Chem., 2010, 45(2), 501-509.
[72]
Velena, A.; Zarkovic, N.; Troselj, K.G.; Bisenieks, E.; Krauze, A.; Poikans, J.; Duburs, G. 1,4-Dihydropyridine derivatives: Dihydronicotinamide analogues - model compounds targeting oxidative stress. Oxid. Med. Cell. Longev., 2016, 2016, 1-35.
[73]
Cabreraa, D.D.C.; Santa-Helenab, E.; Leala, H.P.; Mouraa, R.R.D.; Neryb, L.E.M.; Goncalvesb, C.A.N.; Russowskyc, D.; D’Ocaa, M.A.M. Synthesis and antioxidant activity of new lipophilic dihydropyridines. Bioorg. Chem., 2019, 84, 1-16.
[74]
Yang, G.; Bowei, W.; Shang, G.; Ruhui, Z.; Chunying, Y.; Zheng, S.; Zhihui, L. Design and synthesis of 1,4-dihydropyridine and cinnamic acid esters and their antioxidant properties. Chem. Res. Chin. Univ., 2016, 32(4), 594-599.
[75]
Rucins, M.; Kaldre, D.; Pajuste, K.; Fernandes, M.A.S.; Vicente, J.A.F.; Klimaviciusa, L.; Jaschenko, E.; Kanepe-Lapsa, I.; Shestakova, I.; Plotniece, M.; Gosteva, M.; Sobolev, A.; Jansone, B.; Muceniece, R.; Klusa, V.; Plotniece, A. Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium and/or N-propargyl substituted 1, 4-dihydropyridine derivatives. Comptes Rendus Chem, 2014, 17, 69-80.
[76]
Vijesh, A.M.; Isloor, A.M.; Peethambar, S.K.; Shivananda, K.N.; Arulmoli, T.; Isloor, N.A. Hantzsch reaction: Synthesis and characterization of some new 1, 4-dihydropyridine derivatives as potent antimicrobial and antioxidant agents. Eur. J. Med. Chem., 2011, 46(11), 5591-5597.
[77]
Tirzitis, G.; Tirzite, D.; Hyvonen, Z. Antioxidant Activity of 2,6-Dimethyl-3,5-dialkoxycarbonyl -1,4-dihydropyridines in metal-ion catalyzed lipid peroxidation. Czech J. Food Sci., 2001, 19(3), 81-84.
[78]
Teleb, M.; Zhang, F.; Huang, J.; Gadotti, V.M.; Farghaly, A.M.; Aboulwafa, O.M.; Zamponi, G.W.; Fahmy, H. Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain. Bioorg. Med. Chem., 2017, 26(6), 1926-1938.
[79]
Nangare, A.K.; Kakad, S.B.; Chavan, A.N.; Bole, S.S. Synthesis and signification of 1, 4-dihydropyridines analogs in different pharmaceutical drug. World J. Pharm. Res, 2015, 4(12), 738-749.
[80]
Mishra, B.; Mishra, R. Synthesis of some new 1,4-dihydropyridine derivatives for anti-inflammatory activity. Pharmacist, 2007, 2, 13-16.
[81]
Indumathi, S.; Karthikeyan, R.; Nasser, A.J.A.; Idhayadhulla, A.; Kumar, R.S. Anticonvulsant, analgesic and anti-inflammatory activities of some novel pyrrole and 1,4-dihydropyridine derivatives. J. Chem. Pharm. Res., 2015, 7(2), 434-440.
[82]
Pattan, S.R.; Dighe, N.S.; Musmade, D.S.; Tambe, S.K.; Kale, S.H.; Gaware, V.M.; Chavan, P.A. Synthesis and evaluation of some new substituted 1,4-dihydro pyridine derivatives and their anticonvulsant activity. J. Chem. Pharm. Res., 2010, 2(1), 246-252.
[83]
Samzadeh-Kermani, A.; Shafaroodi, H.; Miri, R.; Mirkhani, H.; Vosooghi, M.; Shafie, A. Lipo philic 2-(4-chlorophenyl)-4-thiazolyl-1,4-dihydropyridines: Synthesis, calcium channel antagonist activity, and protection against pentylenetetrazole-induced seizure. Med. Chem. Res., 2009, 18(2), 112-126.
[84]
Shafiee, A.; Rastkari, N.; Sharifzadeh, M. Anticonvulsant activities of new 1,4-dihydropyridine derivatives containing 4-nitroimidazolyl substituents. DARU-J. Facul. Pharm, 2004, 12(2), 81-86.
[85]
Subudhia, B.B.; Pandab, P.K.; Bhatta, D. Synthesis and antiulcer activity study of 1, 4- dihydropyridines and their Mannich bases with sulfanilamide. Ind J. Chem., 2009, 48, 725-728.
[86]
Kumar, R.S.; Idhayadhulla, A.; Nasser, A.J.A.; Selvin, J. Synthesis and anticoagulant activity of a new series of 1,4-dihydropyridine derivatives. Eur. J. Med. Chem., 2011, 46, 804-810.
[87]
Budriesi, R.; Ioan, P.; Leoni, A.; Pedemonte, N.; Locatelli, A.; Micucci, M.; Chiarini, A.; Galietta, L.J.V. Cystic Fibrosis: A new target for 4-imidazo[2,1-b]thiazole-1, 4-dihydropyridines. J. Med. Chem., 2011, 54, 3885-3894.
[88]
Cateni, F.; Zacchigna, M.; Pedemonte, N.; Galietta, L.J.V.; Mazzei, M.T.; Fossa, P.; Giampieri, M.; Mazzei, M. Synthesis of 4-thiophen-20-yl-1,4-dihydropyridines as potentiators of the CFTR chloride channel. Bioorg. Med. Chem., 2009, 17, 7894-7903.
[89]
Pandey, V.P.; Bisht, S.S.; Mishra, M.M.; Kumar, A.A.; Siddiqi, M.I.; Verma, A.; Mittal, M.; Sane, S.A.; Gupta, S.; Tripathi, R.P. Synthesis and molecular docking studies of 1-phenyl-4-glycosyl-dihydropyridines as potent antileishmanial agents. Eur. J. Med. Chem., 2010, 45, 2381-2385.
[90]
Leon, R.; Rios, C.L.; Marco-Contelles, J.; Huertas, O.; Barril, X.; Luque, F.J.; Lopez, M.G.; Garcia, A.G.; Villarroya, M. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection propertie. Bioorg. Med. Chem., 2008, 16, 7759-7769.
[91]
Contelles, J.M.; Leon, R.; Rios, C.L.; Samadi, A.L.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F.J.; Guez-Franco, M.R.; Lopez, B.; Lopez, A.G.; Garcia, A.G.; Carreiras, M.C.; Villarroya, M. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of alzheimer’s disease. J. Med. Chem., 2009, 52, 2724-2732.
[92]
Milkovic, L.; Vukovic, T.; Zarkovic, N.; Tatzber, F.; Bisenieks, E. Kalme, Z.; Bruvere, I.; Ogle, Z.; Poikans, J.; Velena, A.; Duburs, G. Antioxidative 1,4-dihydropyridine derivativesmodulate oxidative stress and growth of human osteoblast-like cells in vitro. Antioxidants, 2018, 7(9), 123.
[94]
Ohashi, K.; Ebihara, A. Aranidipine (MPC- 1304), A new dihydropyridine calcium antagonist: A review of its antihypertensive action. Cardiovasc. Drug Rev., 1996, 14(1), 1-16.
[97]
Yao, K.; Nagashima, K.; Miki, H. New drugs and recent techniques pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel. J. Pharmacol. Sci., 2006, 261, 243-261.
[98]
Buchiya, F.V.; Jain, V.; Raj, H. A reviewα : analytical methods for determination of cilnidipine in biological fluid and pharmaceutical dosage forms. Pharmatutor, 2014, 2(11), 22-29.
[99]
Keating, G.M. Clevidipine: A review of its use for managing blood pressure in perioperative and intensive care settings. Drugs, 2014, 74, 1947-1960.
[100]
Kastron, V.V.; Vitolin, R.O.; Dubur, G.Y. Synthesis and pharmacological activity of 1,4-dihydropyridine. Translated from Khimiko-farmatsevticheskii Zhurnal, 1991, 24(6), 14-21.
[101]
Vega, J.A.; Sabbatini, M.; Del, M.E.; Amenta, F. Effect of treatment with the dihydropyridine-type calcium antagonist darodipine (PY 108-068) on the expression of neurofilament protein immunoreactivity in the cerebellar cortex of aged rats. Mech. Ageing Dev., 1994, 75, 169-177.
[102]
Amenta, F.; Ferrantea, F.; Mancini, M.; Sabbatinia, M.; Vegab, A.; Zaccheoc, D. Effect of long term treatment with the dihydropyridine-type calcium channel blocker darodipine (PY 108-068) on the cerebral capillary network in aged rats. Mech. Ageing Dev., 1995, 78, 27-37.
[103]
Masuda, Y.; Tanaka, S. Efonidipine Hydrochloride: A new calcium antagonist. cardiovasc. Drug Rev, 1994, 12(2), 123-135.
[104]
Kuhn, A.; Carlsson, J.; Miketic, S.; Tebbe, U. Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina. Cardiovasc. Drugs Ther., 1995, 9, 595-600.
[105]
Mannhold, R.; Jablonkaz, B.; Voigtl, W.; Schgnafinger, K. Calcium- and calmodulin-antagonism of elnadipine derivatives: Comparative SAR. Eur. J. Med. Chem., 1992, 27, 229-235.
[106]
Prisant, M.; Bottini, B.; Dipiro, J.T. Novel drug-delivery systems for hypertension. The Am. J. Med., 1992, 93, 2A-45S-2A-55S.
[107]
Leonetti, G.; Gradnik, R.; Terzoli, L.; Fruscio, M.; Rupoli, L.; Zanchetti, A. Felodipine a new vasodilating drug: Blood pressure, cardiac, renal and humoral effects in hypertensive patients. J. Cardiovasc. Pharmacol., 1984, 6, 392-398.
[108]
Kritchevsky, D.; Tepper, S.A.; Klurfeld, D.M. Flordipine, a calcium channel blocker, which does not influence lipidemia or atherosclerosis in cholesterol-fed rabbits. Atheroscler, 1988, 69, 89-92.
[109]
Alajarin, R.; Vaquero, J.J.; Alvarez-builla, J.; Pastor, M.; Sunkel, C.; Casa-juana, M.F.; Priego, J.; Statkow, P.R.; Sanz-Aparicio, J.; Fonsecall, I. Synthesis, structure, and pharmacological evaluation of the stereoisomers of furnidipine. J. Med. Chem., 1995, 38(15), 2830-2841.
[110]
Krzemi, T.F.; Grzyb, J.; Porc, M.P.; Chatterjee, S.S. Anti-arrhythmic and cardio-protective effects of furnidipine in a rat model: A dose response study. Cardiovasc. Drug Rev., 2006, 549(1-3), 91-97.
[111]
Yamada, S.; Kimura, R. Pharmacodynamics and pharmacokinetics of iganidipine. Cardiovasc. Drug Rev., 1996, 14(3), 213-230.
[112]
Brogden, R.N.; Sorkin, E.M. Mild to moderate hypertension isradipine. Drugs, 1995, 49(4), 618-649.
[113]
Mccormack, P.L.; Wagstaff, A.J.; Meredith, P.A.; Infirmary, W. Lacidipine a review of its use in the management of hypertension. Drugs, 2003, 63(21), 2327-2356.
[114]
Lee, C.R.; Bryson, H.M. Lacidipine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs, 1994, 48(2), 274-296.
[115]
Mcclellan, K.J.; Jarvis, B. Lercanidipine review of its use in hypertension. Drugs, 2000, 60(5), 1123-1140.
[116]
Bang, L.M.; Chapman, T.M.; Goa, K.L. Lercanidipine a review of its efficacy in the management of hypertension. Drugs, 2003, 63(22), 2449-2472.
[117]
Dalal, J.; Mohan, J.C.; Iyengar, S.S.; Hiremath, J. Sathyamurthy, I. Bansal, S. Kahali D Dasbiswas A. S-amlodipine: An isomer with difference - time to shift from racemic amlodipine. Int. J. Hypertens., 2018, 2018(1999), 1-14.
[118]
Cheer, S.M.; Clellan, K.M. Manidipine: A review of its use in hypertension. Drugs, 2001, 61(12), 1777-1799.
[119]
Roca-cusachs, A.; Triposkiadis, F. Antihypertensive effect of manidipine. Drugs, 2005, 65, 2-, 11-19.
[120]
Mckeage, K.; Scott, L.J. Manidipine a review of its use in the management of hypertension. Drugs, 2004, 64(17), 1923-1940.
[121]
Sorkin, E.M.; Clissold, S.P. Nicardipine a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders nicardipine. Drugs, 1987, 345, 296-345.
[122]
Frampton, J.E.; Faulds, D. Nicardipine a review of its pharmacology and therapeutic efficacy in older patients. Drugs Aging, 1993, 3(2), 165-187.
[123]
Michael, J.; Groshong, T.; Tobias, J.D. Nicardipine for hypertensive emergencies in children with renal disease. Pediatr. Nephrol., 1998, 12, 40-42.
[124]
Dollery, C.T.; Murphy, M.B.; Scriven, A.J.I. Role of nifedipine in treatment of hypertension. Br. Med. J., 1983, 287, 257-259.
[125]
Macgregor, G.A. Nifedipine and hypertensionα : Roles of vasodilation and sodium balance. Cardiovasc. Drugs Ther., 1989, 3, 295-301.
[126]
Brennan, F.; Flanagan, M.; Blake, S.; Cannon, P. Nifedipine in the treatment of hypertension. Eur. J. Clin. Pharmacol., 1983, 25, 7-9.
[127]
Romanin, C.; Seyd, K.; Glossmann, H.; Schindler, H. The dihydropyridine niguldipine inhibits T-type Ca2+ currents in atrial myocytes. Eur. J. Physiol., 1992, 420(3-4), 410-412.
[128]
Kreiner, G.; Roman, A.; Zelek-molik, A.; Kowalska, M.; Nalepa, I. Lack of α 1A -adrenergic receptor-mediated antidepressant-like effects of S-(+)- niguldipine and B8805-88033 in the forced swim test. Behav. Pharmacol., 2016, 27(4), 397-401.
[129]
Ishida, S.; Koto, T.; Nagai, N.; Oike, Y. Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular infl ammation in endotoxin-induced uveitis. Jpn. J. Ophthalmol., 2010, 54(6), 594-601.
[130]
Brogden, R.N.; Mctavish, D. Nilvadipine a review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. Drugs Aging, 1995, 6(2), 150-171.
[131]
Hanyu, H.; Hirao, K.; Shimizu, S.; Sato, T.; Kiuchi, A.; Iwamoto, T. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int. J. Geriatr. Psychiat, 2007, 22(12), 1264-1266.
[132]
Langley, M.S.; Sorkin, E.M. Nimodipine a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs, 1989, 37(5), 669-699.
[133]
Muck, W.; Ahr, G.; Kuhlmann, J. Nimodipine potential for drug-drug interactions in the elderly. Drugs Aging, 1995, 6(3), 229-242.
[134]
Goa, K.L.; Sorkin, E.M. Nitrendipine a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs, 1987, 155, 123-155.
[135]
Byyny, R.L.; Loverde, M.; Mitchell, W.; Denver, P.D. Treatment of hypertension in the elderly with a new calcium channel blocking drug, nitrendipine. Am. J. Med., 1989, 86(1), 49-55.
[137]
Fodor, J.G.; Nisoldipine, C.C. Efficacy and tolerability in hypertension and ischemic heart disease. Cardiovasc. Drugs Ther., 1997, 10(3), 873-879.
[138]
Galan, L.; Talavera, K.; Vassort, G.; Alvarez, J.L. Characteristics of Ca 2 channel blockade by oxodipine and elgodipine in rat cardiomyocytes. Eur. J. Pharmacol., 1998, 357, 93-105.
[139]
Karpova, M.N.; Antonikov, I.M.; Pankov, O.Y.; Glebov, R.N. Organic calcium antagonists verapamil and riodipine prevent elevation of free calcium level in rat brain synaptosomes during metrazol kindling. Bull. Exp. Biol. Med., 1992, 114(9), 252-254.
[140]
Tirzite, A.J.; Tirzite, G.D.; Dubur, G.J. Effect of nifedipine and riodipine on biochemical processes in intact erythrocytes. Bull. Exp. Biol. Med., 1991, 110(4), 1358-1360.
[141]
Karpova, M.N.; Abrosimov, I.Y.; Kryzhanovskii, G.N. Effectiveness of combined application of calcium blockers and antiepileptic drugs. Bull. Exp. Biol. Med., 1997, 124(7), 1-4.
[142]
Karpova, M.N.; Kryzhanovskii, G.N.; Abrosimov, I.Y. Antiseizure and neurotoxic effects of various combinations of phenobarbital, diazepam, sodium valproate and 1, 4-dihydropyridine riodipin. Bull. Exp. Biol. Med., 1994, 118(7), 692-695.
[143]
Kim, C.S.; Matsumori, A.; Goldberg, L.; Doye, A.A.; Mccoy, Q.; Gwathmey, J.K. Effects of pranidipine, a calcium channel antagonist, in an avian model of heart failure. Cardiovasc. Drugs Ther., 1999, 13, 455-463.
[144]
Rosenthal, J.; Hittel, N.; Stumpe, K.O. Pranidipine, a novel calcium antagonist, once daily, for the treatment of hypertension: A multicenter, double-blind, placebo-controlled dose-finding study. Cardiovasc. Drugs Ther., 1996, 10(1), 59-66.
Related Books
Science of Spices and Culinary Herbs - Latest Laboratory, Pre-clinical, and Clinical Studies
Frontiers in Natural Product Chemistry
Therapeutic Use of Plant Secondary Metabolites
Therapeutic Implications of Natural Bioactive Compounds
Frontiers in Bioactive Compounds
Frontiers in Natural Product Chemistry
Frontiers in Natural Product Chemistry
Science of Spices and Culinary Herbs - Latest Laboratory, Pre-clinical, and Clinical Studies
Frontiers in Natural Product Chemistry
Frontiers in Natural Product Chemistry
Article Metrics
49
4